Cardium Therapeutics, Inc. (CXM) Positions Itself For Near-Term And Long-Term Growth
Cardium Therapeutics, a San Diego based health sciences and regenerative medicine company, is remarkably well balanced for ongoing growth in the health and therapeutic marketplace. The company has products that cover the range from well-established revenue generators, to relatively recently introduced products just starting to expand commercially, to products still under development.
Cardium subsidiary, To Go Brands, has a wide portfolio of healthy-lifestyle products, already proven in the marketplace and generating dependable revenue. The company sells 100% natural nutraceutical powder mixes, supplements, and chews, all designed for convenient use by health-conscious consumers with an active lifestyle. Although the brands are well established, their presence continues to grow, with new products being developed.
A more recently introduced product, rapidly expanding its market signature, is Cardium's Excellagen, a pharmaceutically-formulated gel that has been shown to promote healing of all types of wounds. Excellagen is for use by doctors, and has been FDA-cleared to treat neuropathic and diabetic foot ulcers, pressure ulcers, venous ulcers, surgical wounds, and other dermal wounds. The company recently announced a distribution agreement with Academy Medical, LLC to market, sell, and distribute Excellagen to U.S. government medical providers, including the Veterans Administration healthcare system and military hospitals, a huge market.
Cardium's longer term product candidate is Generx, a unique DNA-based angiogenic growth factor therapeutic, designed to actually stimulate the growth of blood vessels in the heart, for patients with insufficient blood flow due to heart disease. Unlike traditional drug therapies for heart disease, which are focused simply on reducing pain, Generx is designed to actually encourage the growth of blood vessels. In parts of the world where costly and elaborate heart surgeries are not as readily available, Generx is an important potential new option for the treatment of heart disease. Still under trial, Generx represents the company's major link to future revenue growth.
For additional information, visit CardiumTHX.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.